BRAF inhibition and beyond in advanced melanoma

摘要

In The Lancet , Axel Hauschild and colleagues report results of a phase 3 trial of dabrafenib, an oral inhibitor of mutant BRAF, for the treatment of advanced melanoma. Adult patients with previously untreated, stage IV or unresectable stage III BRAF V600E mutation-positive melanoma were enrolled at centres in 12 countries; 187 were assigned dabrafenib (150 mg twice daily) and 63 were assigned intravenous dacarbazine (1000 mg/m 2 every 3 weeks).